Last edition
News about "Prostate-Specific Membrane Antigen"
Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer
Vir Biotechnology and Astellas are advancing VIR-5500 for late-line metastatic castration-resistant prostate cancer following encouraging preliminary Phase 1 findings.
Prostate-specific Membrane Antigen | 12/10/2026 | By News Bureau
US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer
The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.
Prostate-Specific Membrane Antigen | 03/08/2026 | By News Bureau | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy